BioCentury | Jul 14, 2016
Translation in Brief

Encouraging self-control

...to persistently lower levels of the receptor. Li's team showed that the psoriasis drug Soriatane acitretin...
...marketed by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), might be effective in treating HIV. His group demonstrated Soriatane...
...Center and an assistant professor in the Department of Medicine at UCSF. However, Li said Soriatane...
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: DEAD box polypeptide 58 (DDX58; RIG-I); histone deacetylase (HDAC)

...Infectious disease INDICATION: HIV/AIDS In vitro studies suggest the DDX58 agonist Soriatane acitretin could help treat...
...HIV, Soriatane decreased levels of viral DNA 72 hours after infection compared with vehicle, and Soriatane...
...neither agent alone did so. In CD4+ T cells from HIV patients on antiretroviral therapy, Soriatane...
BioCentury | Apr 16, 2015
Product R&D

Antagonizing psoriasis

...at AnaptysBio. According to Londei, GPP symptoms are usually treated by the oral retinoid Soriatane acitretin...
...in controlling disease progression because they do not target the underlying mechanism. GlaxoSmithKline plc markets Soriatane...
BioCentury | Apr 27, 2009
Company News

Stiefel, GlaxoSmithKline deal

...dermatology market. Stiefel had sales of $900 million in 2008. Stiefel's prescription drugs include Soriatane acitretin...
BioCentury | Apr 21, 2009
Top Story

GSK to acquire Stiefel

...dermatology market. Stiefel had sales of $900 million in 2008. Stiefel's prescription drugs include Soriatane acitretin...
BioCentury | Feb 4, 2008
Clinical News

Soriatane acitretin regulatory update

...Stiefel updated a boxed warning on the label for Soriatane acitretin to inform of the establishment...
...serious teratogenic risks associated with the drug. Female patients are instructed to prevent pregnancies during Soriatane...
...its 2006 acquisition of Connetics Corp. Stiefel Laboratories Inc. , Coral Gables, Fla. Product: Soriatane acitretin...
BioCentury | Oct 30, 2006
Finance

Connetics chronicles

...a market cap peak of around $1 billion in 2004, the same year it in-licensed Soriatane...
...for Evoclin clindamycin (formerly Actiza ) for acne L. 2/9/04 - Acquires U.S. rights to Soriatane...
BioCentury | May 4, 2006
Financial News

Connetics cuts guidance

...year to $211-$217 million from $221-$225 million to reflect the increased competition for psoriasis drug Soriatane...
BioCentury | Mar 13, 2006
Clinical News

Soriatane acitretin: Phase IV data

...U.S. and Russian Phase IV trial in 77 evaluable patients showed that long-term use of Soriatane...
...of Soriatane. Patients received either 25 mg once-daily Soriatane 24 weeks, or 25 mg once-daily Soriatane...
...including plaque, erythrodermic, pastular, guttate and palmer-plantar. Connetics Corp. (CNCT), Palo Alto, Calif. Product: Soriatane acitretin...
BioCentury | Jan 2, 2006
Analyst Picks & Changes

Analyst picks & changes

...SunTrust Robert Hazlett New Neutral -3% $14.45 Hazlett expects generic competition for psoriasis drug Soriatane acitretin...
Items per page:
1 - 10 of 31